{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,21]],"date-time":"2026-08-21T15:17:15Z","timestamp":1787325435393,"version":"build-2736575974"},"reference-count":123,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2017,12,1]],"date-time":"2017-12-01T00:00:00Z","timestamp":1512086400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","croh-online.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Critical Reviews in Oncology\/Hematology"],"published-print":{"date-parts":[[2017,12]]},"DOI":"10.1016\/j.critrevonc.2017.10.011","type":"journal-article","created":{"date-parts":[[2017,10,31]],"date-time":"2017-10-31T20:32:53Z","timestamp":1509481973000},"page":"98-110","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":51,"special_numbering":"C","title":["Incidence of skin toxicity in squamous cell carcinoma of the head and neck treated with radiotherapy and cetuximab: A systematic review"],"prefix":"10.1016","volume":"120","author":[{"given":"Pierluigi","family":"Bonomo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mauro","family":"Loi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isacco","family":"Desideri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emanuela","family":"Olmetto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Camilla","family":"Delli Paoli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca","family":"Terziani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniela","family":"Greto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monica","family":"Mangoni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvia","family":"Scoccianti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriele","family":"Simontacchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giulio","family":"Francolini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Icro","family":"Meattini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saverio","family":"Caini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lorenzo","family":"Livi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.critrevonc.2017.10.011_bib0005","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1016\/j.canrad.2012.06.005","article-title":"Radiotherapy combined with cetuximab for locally advanced head and neck cancer: results and toxicity","volume":"16","author":"Acevedo-Henao","year":"2012","journal-title":"Cancer\/Radiotherapie"},{"issue":"February (4)","key":"10.1016\/j.critrevonc.2017.10.011_bib0010","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1002\/cncr.27741","article-title":"A phase 2 trial of induction nab-paclitaxel and cetuximab given with cisplatin and 5-fluorouracil followed by concurrent cisplatin and radiation for locally advanced squamous cell carcinoma of the head and neck","volume":"119","author":"Adkins","year":"2013","journal-title":"Cancer"},{"key":"10.1016\/j.critrevonc.2017.10.011_bib0015","doi-asserted-by":"crossref","first-page":"148","DOI":"10.4103\/0019-509X.82872","article-title":"Cetuximab with radiotherapy in patients with loco-regionally advanced squamous cell carcinoma of head and neck unsuitable or ineligible for concurrent platinum-based chemo-radiotherapy: ready for routine clinical practice?","volume":"48","author":"Agarwal","year":"2011","journal-title":"Indian J. Cancer"},{"key":"10.1016\/j.critrevonc.2017.10.011_bib0020","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1007\/s00066-011-0006-y","article-title":"Prospective phase II trial of cetuximab plus VMAT-SIB in locally advanced head and neck squamous cell carcinoma: feasibility and tolerability in elderly and chemotherapy-ineligible patients","volume":"188","author":"Alongi","year":"2012","journal-title":"Strahlentherapie Und Onkol"},{"key":"10.1016\/j.critrevonc.2017.10.011_bib0025","doi-asserted-by":"crossref","first-page":"2940","DOI":"10.1200\/JCO.2013.53.5633","article-title":"Randomized phase III trial of concurrent accelerated radiation plus cisplatin with or without cetuximab for stage III to IV head and neck carcinoma: RTOG 0522","volume":"32","author":"Ang","year":"2014","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2017.10.011_bib0030","doi-asserted-by":"crossref","first-page":"5294","DOI":"10.1200\/JCO.2010.30.6423","article-title":"Induction docetaxel, cisplatin, and cetuximab followed by concurrent radiotherapy, cisplatin, and cetuximab and maintenance cetuximab in patients with locally advanced head and neck cancer","volume":"28","author":"Argiris","year":"2010","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2017.10.011_bib0035","doi-asserted-by":"crossref","first-page":"2482","DOI":"10.1093\/annonc\/mdr002","article-title":"Phase I trial of pemetrexed in combination with cetuximab and concurrent radiotherapy in patients with head and neck cancer","volume":"22","author":"Argiris","year":"2011","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.critrevonc.2017.10.011_bib0040","doi-asserted-by":"crossref","first-page":"1729","DOI":"10.1007\/s00520-011-1266-x","article-title":"Using the skindex-16 and common terminology criteria for adverse events to assess rash symptoms: results of a pooled-analysis (N0993)","volume":"20","author":"Atherton","year":"2012","journal-title":"Support. Care Cancer"},{"key":"10.1016\/j.critrevonc.2017.10.011_bib0045","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1007\/s00066-009-2092-7","article-title":"Combined cetuximab and reirradiation for locoregional recurrent and inoperable squamous cell carcinoma of the head and neck","volume":"185","author":"Balermpas","year":"2009","journal-title":"Strahlentherapie Und Onkol"},{"key":"10.1016\/j.critrevonc.2017.10.011_bib0050","first-page":"3","article-title":"Reirradiation with cetuximab in locoregional recurrent and inoperable squamous cell carcinoma of the head and neck: feasibility and first efficacy results","volume":"8","author":"Balermpas","year":"2012","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"10.1016\/j.critrevonc.2017.10.011_bib0055","doi-asserted-by":"crossref","first-page":"1346","DOI":"10.1016\/j.ijrobp.2016.03.011","article-title":"Correlation between the severity of cetuximab-Induced skin rash and clinical outcome for head and neck cancer patients: the RTOG experience","volume":"95","author":"Bar-Ad","year":"2016","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"issue":"6","key":"10.1016\/j.critrevonc.2017.10.011_bib0060","first-page":"1","article-title":"Phase I trial of cetuximab, intensity modulated radiotherapy (IMRT), and ipilimumab in previously untreated, locally advanced head and neck squamous cell carcinoma","volume":"27","author":"Bauman","year":"2016","journal-title":"Ann. Oncol."},{"issue":"February (1)","key":"10.1016\/j.critrevonc.2017.10.011_bib0065","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1111\/coa.12002","article-title":"Outcome and toxicity of radiotherapy combined with chemotherapy or cetuximab for head and neck cancer: our experience in one hundred and twenty-five patients","volume":"38","author":"Beijer","year":"2013","journal-title":"Clin. Otolaryngol."},{"key":"10.1016\/j.critrevonc.2017.10.011_bib0070","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1093\/annonc\/mdm400","article-title":"Consensus guidelines for the management of radiation dermatitis and coexisting acne-like rash in patients receiving radiotherapy plus EGFR inhibitors for the treatment of squamous cell carcinoma of the head and neck","volume":"19","author":"Bernier","year":"2008","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.critrevonc.2017.10.011_bib0075","doi-asserted-by":"crossref","first-page":"2191","DOI":"10.1093\/annonc\/mdr139","article-title":"Management of radiation dermatitis in patients receiving cetuximab and radiotherapy for locally advanced squamous cell carcinoma of the head and neck: proposals for a revised grading system and consensus management guidelines","volume":"22","author":"Bernier","year":"2011","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.critrevonc.2017.10.011_bib0080","doi-asserted-by":"crossref","first-page":"1360","DOI":"10.1016\/j.ijrobp.2009.04.005","article-title":"Weekly volume and dosimetric changes during chemoradiotherapy with intensity-Modulated radiation therapy for head and neck cancer: a prospective observational study","volume":"76","author":"Bhide","year":"2010","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"issue":"July (5)","key":"10.1016\/j.critrevonc.2017.10.011_bib0085","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1016\/j.canrad.2016.05.009","article-title":"Toxicity and efficacy of cetuximab associated with several modalities of IMRT for locally advanced head and neck cancer","volume":"20","author":"Bibault","year":"2016","journal-title":"Cancer Radiother."},{"key":"10.1016\/j.critrevonc.2017.10.011_bib0090","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1097\/COC.0b013e3181979093","article-title":"Cetuximab, paclitaxel, carboplatin, and radiation for head and neck cancer: a toxicity analysis","volume":"33","author":"Birnbaum","year":"2010","journal-title":"Am. J. Clin. Oncol."},{"issue":"April (2)","key":"10.1016\/j.critrevonc.2017.10.011_bib0095","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1097\/COC.0b013e31826e06e0","article-title":"Cetuximab, paclitaxel, carboplatin, and radiatio for head and neck cancer: a survival analysis of a brown university oncology group phase II study","volume":"37","author":"Birnbaum","year":"2014","journal-title":"Am. J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2017.10.011_bib0100","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1056\/NEJMoa053422","article-title":"Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck","volume":"354","author":"Bonner","year":"2006","journal-title":"NEJM"},{"key":"10.1016\/j.critrevonc.2017.10.011_bib0105","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/S1470-2045(09)70311-0","article-title":"Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-year survival data from a phase 3 randomised trial, and relation between cetuximab-induced rash and survival","volume":"11","author":"Bonner","year":"2010","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.critrevonc.2017.10.011_bib0110","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1016\/j.radonc.2015.05.018","article-title":"Identifying patients who may benefit from adaptive radiotherapy: does the literature on anatomic and dosimetric changes in head and neck organs at risk during radiotherapy provide information to help?","volume":"115","author":"Brouwer","year":"2015","journal-title":"Radiother. Oncol."},{"key":"10.1016\/j.critrevonc.2017.10.011_bib0115","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1016\/j.ijrobp.2009.04.066","article-title":"A retrospective, multicenter study of the tolerance of induction chemotherapy with docetaxel cisplatin, and 5-Fluorouracil followed by radiotherapy with concomitant cetuximab in 46 cases of squamous cell carcinoma of the head and neck","volume":"77","author":"Buiret","year":"2010","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"issue":"April (4)","key":"10.1016\/j.critrevonc.2017.10.011_bib0120","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1016\/j.oraloncology.2011.10.019","article-title":"Management of dermatitis in patients with locally advanced squamous cell carcinoma of the head and neck receiving cetuximab and radiotherapy","volume":"48","author":"Cabez\u00f3n-Guti\u00e9rrez","year":"2012","journal-title":"Oral Oncol."},{"issue":"5","key":"10.1016\/j.critrevonc.2017.10.011_bib0125","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1159\/000355579","article-title":"Management of \u2018in-field' skin toxicity in head and neck cancer patients treated with combined cetuximab and radiotherapy","volume":"85","author":"Cante","year":"2013","journal-title":"Oncology"},{"key":"10.1016\/j.critrevonc.2017.10.011_bib0130","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1016\/j.clon.2011.11.005","article-title":"Adaptive radiotherapy using helical tomotherapy for head and neck cancer in definitive and postoperative settings: initial results","volume":"24","author":"Capelle","year":"2012","journal-title":"Clin. Oncol."},{"issue":"July (3)","key":"10.1016\/j.critrevonc.2017.10.011_bib0135","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1016\/j.ijrobp.2007.10.040","article-title":"Locoregionally advanced head and neck cancer treated with primary radiotherapy: a comparison of the addition of cetuximab or chemotherapy and the impact of protocol treatment","volume":"71","author":"Caudell","year":"2008","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"10.1016\/j.critrevonc.2017.10.011_bib0140","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1016\/j.radonc.2009.05.005","article-title":"Radiotherapy compliance is maintained with hypofractionation and concurrent cetuximab in locally advanced head and neck cancer","volume":"93","author":"Chan","year":"2009","journal-title":"Radiother. Oncol."},{"key":"10.1016\/j.critrevonc.2017.10.011_bib0145","doi-asserted-by":"crossref","first-page":"2191","DOI":"10.1200\/JCO.2006.08.8005","article-title":"Quality of life in head and neck cancer patients after treatment with high-dose radiotherapy alone or in combination with cetuximab","volume":"25","author":"Curran","year":"2007","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2017.10.011_bib0150","doi-asserted-by":"crossref","first-page":"154","DOI":"10.4103\/0019-509X.82873","article-title":"Cetuximab plus radiotherapy in patients with unresectable locally advanced squamous cell carcinoma of head and neck region\u2013a open labelled single arm phase II study","volume":"48","author":"Dattatreya","year":"2011","journal-title":"Indian J. Cancer"},{"issue":"4","key":"10.1016\/j.critrevonc.2017.10.011_bib0155","doi-asserted-by":"crossref","first-page":"166","DOI":"10.12968\/jowc.2011.20.4.166","article-title":"Wound healing following combined radiation and cetuximab therapy in ahead and neck cancer patients","volume":"20","author":"Dean","year":"2011","journal-title":"J. Wound Care"},{"issue":"June","key":"10.1016\/j.critrevonc.2017.10.011_bib0160","doi-asserted-by":"crossref","first-page":"165","DOI":"10.2147\/CMAR.S11085","article-title":"Cetuximab in the treatment of head and neck cancer: preliminary results outside clinical trials","volume":"2","author":"Dequanter","year":"2010","journal-title":"Cancer Manag Res."},{"issue":"October (19)","key":"10.1016\/j.critrevonc.2017.10.011_bib0165","doi-asserted-by":"crossref","first-page":"5041","DOI":"10.1158\/1078-0432.CCR-14-0051","article-title":"Phase II study of cetuximab in combination with cisplatin and radiation in unresectable, locally advanced head and neck squamous cell carcinoma: eastern cooperative oncology group trial E3303","volume":"20","author":"Egloff","year":"2014","journal-title":"Clin. Cancer Res."},{"issue":"July (6)","key":"10.1016\/j.critrevonc.2017.10.011_bib0170","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1097\/CAD.0b013e328360b9d6","article-title":"Neoadjuvant TPF in locally advanced head and neck cancer can be followed by radiotherapy combined with cisplatin or cetuximab: a study of 157 patients","volume":"24","author":"Fayette","year":"2013","journal-title":"Anticancer Drugs."},{"key":"10.1016\/j.critrevonc.2017.10.011_bib0175","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1007\/s12032-014-0170-x","article-title":"Toxicity of concurrent chemoradiotherapy with cetuximab for locoregionally advanced nasopharyngeal carcinoma","volume":"31","author":"Feng","year":"2014","journal-title":"Med. Oncol."},{"key":"10.1016\/j.critrevonc.2017.10.011_bib0180","first-page":"2009","article-title":"MMP9 but Not EGFR, MET, ERCC1, P16, and P \u221253 is associated with response to concomitant radiotherapy, cetuximab, and weekly cisplatin in patients with locally advanced head and neck cancer","author":"Fountzilas","year":"2009","journal-title":"J Oncol"},{"key":"10.1016\/j.critrevonc.2017.10.011_bib0185","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1093\/annonc\/mdt579","article-title":"Phase I study of weekly nab-paclitaxel\u2009+\u2009weekly cetuximab\u2009+\u2009intensity-modulated radiation therapy (IMRT) in patients with stage III-IVB head and neck squamous cell carcinoma (HNSCC)","volume":"25","author":"Fury","year":"2014","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.critrevonc.2017.10.011_bib0190","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1016\/j.radonc.2008.09.007","article-title":"High rate of severe radiation dermatitis during radiation therapy with concurrent cetuximab in head and neck cancer: results of a survey in EORTC institutes","volume":"90","author":"Giro","year":"2009","journal-title":"Radiother. Oncol."},{"issue":"September (27)","key":"10.1016\/j.critrevonc.2017.10.011_bib0195","doi-asserted-by":"crossref","first-page":"4448","DOI":"10.1200\/JCO.2009.22.1333","article-title":"Phase I study of C-TPF in patients with locally advanced squamous cell carcinoma of the head and neck","volume":"27","author":"Haddad","year":"2009","journal-title":"J. Clin. Oncol."},{"issue":"August (23)","key":"10.1016\/j.critrevonc.2017.10.011_bib0200","doi-asserted-by":"crossref","first-page":"2486","DOI":"10.1200\/JCO.2013.53.9163","article-title":"Postoperative chemoradiotherapy and cetuximab for high-risk squamous cell carcinoma of the head and neck: radiation Therapy Oncology Group RTOG-0234","volume":"32","author":"Harari","year":"2014","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2017.10.011_bib0205","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1016\/S1470-2045(09)70348-1","article-title":"Rash conclusions from a phase 3 study of cetuximab?","volume":"11","author":"Harrington","year":"2010","journal-title":"Lancet Oncol."},{"issue":"October (10)","key":"10.1016\/j.critrevonc.2017.10.011_bib0210","doi-asserted-by":"crossref","first-page":"1459","DOI":"10.2217\/fon.13.151","article-title":"Cetuximab in combination with chemoradiation after induction chemotherapy of locoregionally advanced nasopharyngeal carcinoma: preliminary results","volume":"9","author":"He","year":"2013","journal-title":"Future Oncol."},{"issue":"April (2)","key":"10.1016\/j.critrevonc.2017.10.011_bib0215","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1097\/COC.0b013e3181dbb73e","article-title":"Concurrent cetuximab with stereotactic body radiotherapy for recurrent squamous cell carcinoma of the head and neck: a single institution matched case-control study","volume":"34","author":"Heron","year":"2011","journal-title":"Am. J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2017.10.011_bib0220","series-title":"Assessing Risk of Bias in Included Studies. Cochrane Handbook for Systematic Reviews of Interventions","first-page":"187","author":"Higgins","year":"2008"},{"key":"10.1016\/j.critrevonc.2017.10.011_bib0225","article-title":"Cisplatin-based chemotherapy versus cetuximab in concurrent chemoradiotherapy for locally advanced head and neck cancer treatment","volume":"201","author":"Hu","year":"2014","journal-title":"BioMed Res. Int."},{"issue":"April (2)","key":"10.1016\/j.critrevonc.2017.10.011_bib0230","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1007\/s10147-013-0540-y","article-title":"A matched-pair comparison of intensity-modulated radiation therapy with cetuximab versus intensity-modulated radiation therapy with platinum-based chemotherapy for locally advanced head neck cancer","volume":"19","author":"Huang","year":"2014","journal-title":"Int. J. Clin. Oncol."},{"issue":"September","key":"10.1016\/j.critrevonc.2017.10.011_bib0235","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1186\/1748-717X-6-122","article-title":"Disease control and functional outcome in three modern combined organ preserving regimens for locally advanced squamous cell carcinoma of the head and neck (SCCHN)","volume":"6","author":"Jensen","year":"2011","journal-title":"Radiat. Oncol."},{"key":"10.1016\/j.critrevonc.2017.10.011_bib0240","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1186\/1748-717X-7-57","article-title":"Radiochemoimmunotherapy with intensity-modulated concomitant boost: interim analysis of the REACH trial","volume":"7","author":"Jensen","year":"2012","journal-title":"Radiat. Oncol."},{"key":"10.1016\/j.critrevonc.2017.10.011_bib0245","doi-asserted-by":"crossref","first-page":"2137","DOI":"10.1200\/JCO.2005.05.2308","article-title":"Patterns of cancer incidence, mortality, and prevalence across five continents: defining priorities to reduce cancer disparities in different geographic regions of the world","volume":"24","author":"Kamangar","year":"2006","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2017.10.011_bib0250","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1002\/cncr.25374","article-title":"Phase 2 trial of concurrent 5-fluorouracil, hydroxyurea, cetuximab, and hyperfractionated intensity-modulated radiation therapy for locally advanced head and neck cancer","volume":"117","author":"Kao","year":"2011","journal-title":"Cancer"},{"key":"10.1016\/j.critrevonc.2017.10.011_bib0255","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1016\/j.ejca.2012.08.004","article-title":"Induction chemotherapy with docetaxel, cisplatin and 5-fluorouracil followed by radiotherapy with cetuximab for locally advanced squamous cell carcinoma of the head and neck","volume":"49","author":"Keil","year":"2013","journal-title":"Eur. J. Cancer"},{"issue":"January-February (1)","key":"10.1016\/j.critrevonc.2017.10.011_bib0260","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.amjoto.2011.02.004","article-title":"A retrospective study of induction chemotherapy with docetaxel, cisplatinum, and 5-fluorouracil followed by concurrent radiotherapy with cetuximab in locally advanced head and neck cancer","volume":"33","author":"Kim","year":"2012","journal-title":"Am. J. Otolaryngol."},{"key":"10.1016\/j.critrevonc.2017.10.011_bib0265","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.ijrobp.2009.04.060","article-title":"Radiochemotherapy with cetuximab cisplatin, and amifostine for locally advanced head and neck cancer: a feasibility study","volume":"77","author":"Koukourakis","year":"2010","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"10.1016\/j.critrevonc.2017.10.011_bib0270","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1097\/COC.0b013e318193125c","article-title":"Severe radiation dermatitis in patients with locally advanced head and neck cancer treated with concurrent radiation and cetuximab","volume":"32","author":"Koutcher","year":"2009","journal-title":"Am. J. Clin. Oncol."},{"issue":"November (4)","key":"10.1016\/j.critrevonc.2017.10.011_bib0275","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1016\/j.ijrobp.2010.07.008","article-title":"Concurrent cisplatin and radiation versus cetuximab and radiation for locally advanced head-and-neck cancer","volume":"81","author":"Koutcher","year":"2011","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"10.1016\/j.critrevonc.2017.10.011_bib0280","doi-asserted-by":"crossref","first-page":"2284","DOI":"10.1093\/annonc\/mdq216","article-title":"Phase I trial of dose-escalated cisplatin with concomitant cetuximab and hyperfractionated-accelerated radiotherapy in locally advanced squamous cell carcinoma of the head and neck","volume":"21","author":"Kuhnt","year":"2010","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.critrevonc.2017.10.011_bib0285","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1093\/jrr\/rrv038","article-title":"Initial experience of radiotherapy plus cetuximab for Japanese head and neck cancer patients. J","volume":"56","author":"Kurokawa","year":"2015","journal-title":"Radiat. Res."},{"key":"10.1016\/j.critrevonc.2017.10.011_bib0290","doi-asserted-by":"crossref","first-page":"2157","DOI":"10.1093\/annonc\/mdr410","article-title":"Grading system and management guidelines for dermatitis induced by head and neck radiotherapy plus cetuximab: clinical validation required","volume":"22","author":"Langendijk","year":"2011","journal-title":"Ann. Oncol."},{"issue":"November (2)","key":"10.1016\/j.critrevonc.2017.10.011_bib0295","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/j.radonc.2013.08.012","article-title":"Multi institutional phase II study of concomitant stereotactic reirradiation and cetuximab for recurrent head and neck cancer","volume":"109","author":"Lartigau","year":"2013","journal-title":"Radiother. Oncol."},{"key":"10.1016\/j.critrevonc.2017.10.011_bib0300","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1016\/S0360-3016(02)02756-6","article-title":"Skin toxicity due to intensity-modulated radiotherapy for head-and-neck carcinoma","volume":"53","author":"Lee","year":"2002","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"10.1016\/j.critrevonc.2017.10.011_bib0305","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1200\/JCO.2012.42.3988","article-title":"Induction chemotherapy followed by either chemoradiotherapy or bioradiotherapy for larynx preservation: the TREMPLIN randomized phase II study","volume":"31","author":"Lefebvre","year":"2013","journal-title":"J. Clin. Oncol."},{"issue":"December (12)","key":"10.1016\/j.critrevonc.2017.10.011_bib0310","doi-asserted-by":"crossref","first-page":"2253","DOI":"10.1185\/03007995.2011.633989","article-title":"Corral M, et al. Indirect comparison of the efficacy of cetuximab and cisplatin in squamous cell carcinoma of the head and neck","volume":"27","author":"Levy","year":"2011","journal-title":"Curr. Med. Res. Opin."},{"key":"10.1016\/j.critrevonc.2017.10.011_bib0315","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1007\/s00066-014-0626-0","article-title":"Concurrent use of cisplatin or cetuximab with definitive radiotherapy for locally advanced head and neck squamous cell carcinomas","volume":"190","author":"Levy","year":"2014","journal-title":"Strahlenther. Onkol."},{"key":"10.1016\/j.critrevonc.2017.10.011_bib0320","doi-asserted-by":"crossref","first-page":"E905","DOI":"10.1002\/hed.24125","article-title":"Toxicity of concomitant cetuximab and radiotherapy with or without initial taxane-based induction chemotherapy in locally advanced head and neck cancer","author":"Levy","year":"2016","journal-title":"Head Neck"},{"issue":"5","key":"10.1016\/j.critrevonc.2017.10.011_bib0325","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1159\/000355194","article-title":"Cisplatin versus cetuximab given concurrently with definitive radiation therapy for locally advanced head and neck squamous cell carcinoma","volume":"85","author":"Ley","year":"2013","journal-title":"Oncology"},{"key":"10.1016\/j.critrevonc.2017.10.011_bib0330","article-title":"The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration","volume":"62","author":"Liberati","year":"2009","journal-title":"BMJ"},{"key":"10.1016\/j.critrevonc.2017.10.011_bib0335","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/j.clon.2007.09.003","article-title":"Cetuximab is effective, but more toxic than reported in the bonner trial","volume":"20","author":"Lord","year":"2008","journal-title":"Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2017.10.011_bib0340","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1093\/annonc\/mdr401","article-title":"A phase II study of concurrent cetuximab-cisplatin and intensity-modulated radiotherapy in locoregionally advanced nasopharyngeal carcinoma","volume":"23","author":"Ma","year":"2012","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.critrevonc.2017.10.011_bib0345","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1200\/JCO.2015.63.1671","article-title":"Cetuximab and radiotherapy versus cisplatin and radiotherapy for locally advanced head and neck cancer: a randomized phase II trial","volume":"34","author":"Magrini","year":"2016","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2017.10.011_bib0350","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1007\/s00066-013-0378-2","article-title":"Feasibility of 6-month maintenance cetuximab after adjuvant concurrent chemoradiation plus cetuximab in squamous cell carcinoma of the head and neck","volume":"189","author":"Matuschek","year":"2013","journal-title":"Strahlentherapie Und Onkol"},{"key":"10.1016\/j.critrevonc.2017.10.011_bib0355","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1093\/annonc\/mdq412","article-title":"Cisplatin-based chemoradiation plus cetuximab in locally advanced head and neck cancer: a phase II clinical study","volume":"22","author":"Merlano","year":"2011","journal-title":"Ann. Oncol."},{"issue":"February (2)","key":"10.1016\/j.critrevonc.2017.10.011_bib0360","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1093\/annonc\/mds291","article-title":"Adjuvant therapy with cetuximab for locally advanced squamous cell carcinoma of the oropharynx: results from a randomized, phase II prospective trial","volume":"24","author":"Mes\u00eda","year":"2013","journal-title":"Ann. Oncol."},{"issue":"February (2)","key":"10.1016\/j.critrevonc.2017.10.011_bib0365","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1016\/j.ijrobp.2015.10.019","article-title":"A phase 2 open label, single-Arm trial to evaluate the combination of cetuximab plus taxotere cisplatin, and 5-Flurouracil as an induction regimen in patients with unresectable squamous cell carcinoma of the head and neck","volume":"94","author":"Mesia","year":"2016","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"issue":"October (10)","key":"10.1016\/j.critrevonc.2017.10.011_bib0370","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1007\/s00066-013-0402-6","article-title":"Reirradiation plus EGFR inhibition in locally recurrent and unresectable head and neck cancer: final results from a single institution","volume":"189","author":"Milanovi\u0107","year":"2013","journal-title":"Strahlenther. Onkol."},{"issue":"5","key":"10.1016\/j.critrevonc.2017.10.011_bib0375","doi-asserted-by":"crossref","first-page":"e845","DOI":"10.1016\/j.ijrobp.2010.10.021","article-title":"IMRT with simultaneous integrated boost and concurrent chemotherapy for locoregionally advanced squamous cell carcinoma of the head and neck","volume":"81","author":"Montejo","year":"2011","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"10.1016\/j.critrevonc.2017.10.011_bib0380","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1007\/s00432-013-1419-z","article-title":"Experience with combination of cetuximab plus intensity-modulated radiotherapy with or without chemotherapy for locoregionally advanced nasopharyngeal carcinoma","volume":"139","author":"Niu","year":"2013","journal-title":"J. Cancer Res. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2017.10.011_bib0385","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1093\/jjco\/hyt030","article-title":"Phase II study of cetuximab plus concomitant boost radiotherapy in Japanese patients with locally advanced squamous cell carcinoma of the head and neck","volume":"43","author":"Okano","year":"2013","journal-title":"Jpn. J. Clin. Oncol."},{"issue":"January (13)","key":"10.1016\/j.critrevonc.2017.10.011_bib0390","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1186\/1471-2407-13-26","article-title":"Differential outcome of concurrent radiotherapy plus epidermal growth factor receptor inhibitors versus radiotherapy plus cisplatin in patients with human papillomavirus-related head and neck cancer","volume":"18","author":"Pajares","year":"2013","journal-title":"BMC Cancer"},{"key":"10.1016\/j.critrevonc.2017.10.011_bib0395","doi-asserted-by":"crossref","first-page":"1072","DOI":"10.1200\/JCO.2004.00.1792","article-title":"Concurrent cetuximab, cisplatin, and concomitant boost radiotherapy for locoregionally advanced, squamous cell head and neck cancer: a pilot phase II study of a new combined-modality paradigm","volume":"24","author":"Pfister","year":"2006","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2017.10.011_bib0400","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.radonc.2009.04.014","article-title":"Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): An update on 93 randomised trials and 17,346 patients","volume":"92","author":"Pignon","year":"2009","journal-title":"Radiother. Oncol."},{"key":"10.1016\/j.critrevonc.2017.10.011_bib0405","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1634\/theoncologist.2010-0298","article-title":"Management of skin toxicity associated with cetuximab treatment in combination with chemotherapy or radiotherapy","volume":"16","author":"Pinto","year":"2011","journal-title":"Oncologist"},{"issue":"August (4)","key":"10.1016\/j.critrevonc.2017.10.011_bib0410","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1097\/COC.0000000000000291","article-title":"Management of skin reactions during cetuximab treatment in association with chemotherapy or radiotherapy: update of the italian expert recommendations","volume":"39","author":"Pinto","year":"2016","journal-title":"Am. J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2017.10.011_bib0415","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.prro.2013.04.002","article-title":"Planning target volume-to-skin proximity for head-and-neck intensity modulated radiation therapy treatment planning","volume":"4","author":"Price","year":"2014","journal-title":"Pract Radiat Oncol"},{"key":"10.1016\/j.critrevonc.2017.10.011_bib0420","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1016\/j.radonc.2008.09.018","article-title":"Enhanced toxicity with concurrent cetuximab and radiotherapy in head and neck cancer","volume":"90","author":"Pryor","year":"2009","journal-title":"Radiother. Oncol."},{"key":"10.1016\/j.critrevonc.2017.10.011_bib0425","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1016\/j.oraloncology.2011.07.023","article-title":"Distinct patterns of stomatitis with concurrent cetuximab and radiotherapy for head and neck squamous cell carcinoma","volume":"47","author":"Pryor","year":"2011","journal-title":"Oral Oncol."},{"key":"10.1016\/j.critrevonc.2017.10.011_bib0430","doi-asserted-by":"crossref","first-page":"S138","DOI":"10.1016\/S0167-8140(16)31547-X","article-title":"Phase I results of PARPi (Olaparib) + RT + cetuximab in LAHNSCC","volume":"119","author":"Raben","year":"2016","journal-title":"Radiother. Oncol."},{"key":"10.1016\/j.critrevonc.2017.10.011_bib0435","first-page":"195","article-title":"Efficacy and feasibility of induction chemotherapy and radiotherapy plus cetuximab in head and neck cancer","volume":"32","author":"Rampino","year":"2012","journal-title":"Anticancer Res."},{"issue":"March (3)","key":"10.1016\/j.critrevonc.2017.10.011_bib0440","doi-asserted-by":"crossref","first-page":"e3","DOI":"10.1016\/j.oraloncology.2012.02.008","article-title":"Dermatitis associated with cetuximab and radiotherapy: the potential benefit with recombinant human epidermal growth factor and a concern regarding the use of steroids","volume":"49","author":"Revannasiddaiah","year":"2013","journal-title":"Oral Oncol."},{"issue":"January (2)","key":"10.1016\/j.critrevonc.2017.10.011_bib0445","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1200\/JCO.2012.46.9049","article-title":"Should cetuximab replace Cisplatin for definitive chemoradiotherapy in locally advanced head and neck cancer?","volume":"31","author":"Riaz","year":"2013","journal-title":"Am. J. Clin. Oncol."},{"issue":"February (1)","key":"10.1016\/j.critrevonc.2017.10.011_bib0450","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1097\/COC.0000000000000006","article-title":"Concurrent chemoradiotherapy with cisplatin versus cetuximab for squamous cell carcinoma of the head and neck","volume":"39","author":"Riaz","year":"2016","journal-title":"Am. J. Clin. Oncol."},{"issue":"2","key":"10.1016\/j.critrevonc.2017.10.011_bib0455","doi-asserted-by":"crossref","first-page":"183","DOI":"10.3109\/09546634.2014.927815","article-title":"Adverse skin reactions during treatment with cetuximab plus radiotherapy: multidisciplinary approach to minimize radio-chemotherapy interruption","volume":"26","author":"Ricci","year":"2015","journal-title":"J. Dermatolog. Treat."},{"key":"10.1016\/j.critrevonc.2017.10.011_bib0460","doi-asserted-by":"crossref","first-page":"1300","DOI":"10.1200\/JCO.2015.62.5970","volume":"34","author":"Rosenthal","year":"2016","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2017.10.011_bib0465","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1016\/j.ijrobp.2007.05.063","article-title":"Ultrathin hydrocolloid dressing in skin damaged from alternating radiotherapy and chemotherapy plus cetuximab in advanced head and neck cancer (G. O. N. O. AlteRCC italian trial): In regard to macmillan et al. (Int\u2009J radiat oncol biol phys 2007;68:864-872)","volume":"69","author":"Russi","year":"2007","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"issue":"September (9)","key":"10.1016\/j.critrevonc.2017.10.011_bib0470","doi-asserted-by":"crossref","first-page":"2463","DOI":"10.1093\/annonc\/mdt281","article-title":"Bio-radiation dermatitis: the need of a new grading: in regard to Bernier et al: ann Oncol 2011; 22(10): 2191\u20132200","volume":"24","author":"Russi","year":"2013","journal-title":"Ann. Oncol."},{"issue":"October (1)","key":"10.1016\/j.critrevonc.2017.10.011_bib0475","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/j.critrevonc.2015.06.001","article-title":"Acute skin toxicity management in head and neck cancer patients treated with radiotherapy and chemotherapy or EGFR inhibitors: literature review and consensus","volume":"96","author":"Russi","year":"2015","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"10.1016\/j.critrevonc.2017.10.011_bib0480","doi-asserted-by":"crossref","first-page":"165","DOI":"10.3389\/fonc.2014.00165","article-title":"Concurrent radiotherapy with Carboplatin and cetuximab for the treatment of medically compromised patients with locoregionally advanced head and neck squamous cell carcinoma","volume":"4","author":"Saigal","year":"2014","journal-title":"Front. Oncol."},{"key":"10.1016\/j.critrevonc.2017.10.011_bib0485","first-page":"1","article-title":"Comparison of acute toxicities associated with cetuximab-based bioradiotherapy and platinum-based chemoradiotherapy for head and neck squamous cell carcinomas: a single-institution retrospective study in Japan","author":"Sakashita","year":"2015","journal-title":"Acta Otolaryngol."},{"key":"10.1016\/j.critrevonc.2017.10.011_bib0490","doi-asserted-by":"crossref","first-page":"1355","DOI":"10.1016\/j.ijrobp.2016.05.015","article-title":"How much of the future can Be read through the skin?","volume":"95","author":"Sanguineti","year":"2016","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"10.1016\/j.critrevonc.2017.10.011_bib0495","doi-asserted-by":"crossref","first-page":"4499","DOI":"10.1158\/1078-0432.CCR-14-0348","article-title":"A let-7 microRNA-binding site polymorphism in KRAS predicts improved outcome in patients with metastatic colorectal cancer treated with salvage cetuximab\/panitumumab monotherapy","volume":"20","author":"Saridaki","year":"2014","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.critrevonc.2017.10.011_bib0500","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1007\/s00066-011-2217-7","article-title":"Incidence of dermatitis in head and neck cancer patients treated with primary radiotherapy and cetuximab","volume":"187","author":"Selzer","year":"2011","journal-title":"Strahlentherapie Und Onkol"},{"issue":"October (10)","key":"10.1016\/j.critrevonc.2017.10.011_bib0505","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1016\/j.oraloncology.2014.07.001","article-title":"Efficacy of concurrent cetuximab vs. 5-fluorouracil\/carboplatin or high-dose cisplatin with intensity-modulated radiation therapy (IMRT) for locally-advanced head and neck cancer (LAHNSCC)","volume":"50","author":"Shapiro","year":"2014","journal-title":"Oral Oncol."},{"issue":"November (11)","key":"10.1016\/j.critrevonc.2017.10.011_bib0510","doi-asserted-by":"crossref","first-page":"1555","DOI":"10.1002\/hed.23506","article-title":"TPF induction chemotherapy and concomitant irradiation with cisplatin and cetuximab in unresectable squamous cell carcinoma of the head and neck","volume":"36","author":"Strojan","year":"2014","journal-title":"Head Neck"},{"issue":"July (7)","key":"10.1016\/j.critrevonc.2017.10.011_bib0515","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1016\/j.oraloncology.2015.04.012","article-title":"Comparison of every 3 week cisplatin or weekly cetuximab with concurrent radiotherapy for locally advanced head and neck cancer","volume":"51","author":"Strom","year":"2015","journal-title":"Oral Oncol."},{"key":"10.1016\/j.critrevonc.2017.10.011_bib0520","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/j.ijrobp.2010.05.018","article-title":"Grade 3\/4 dermatitis in head and neck cancer patients treated with concurrent cetuximab and IMRT","volume":"81","author":"Studer","year":"2011","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"10.1016\/j.critrevonc.2017.10.011_bib0525","doi-asserted-by":"crossref","first-page":"1845","DOI":"10.1016\/j.ijrobp.2011.02.062","article-title":"Phase II study evaluating the addition of cetuximab to the concurrent delivery of weekly carboplatin, paclitaxel, and daily radiotherapy for patients with locally advanced squamous cell carcinomas of the head and neck","volume":"82","author":"Suntharalingam","year":"2012","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"issue":"March (3)","key":"10.1016\/j.critrevonc.2017.10.011_bib0530","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1002\/hed.23609","article-title":"Concurrent cetuximab versus platinum-based chemoradiation for the definitive treatment of locoregionally advanced head and neck cancer","volume":"37","author":"Tang","year":"2015","journal-title":"Head Neck"},{"key":"10.1016\/j.critrevonc.2017.10.011_bib0535","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1016\/j.clon.2008.07.003","article-title":"Hypofractionated radiotherapy plus cetuximab in locally advanced head and neck cancer","volume":"20","author":"Teoh","year":"2008","journal-title":"Clin Oncol R Coll Radiol Gt Britain"},{"key":"10.1016\/j.critrevonc.2017.10.011_bib0540","doi-asserted-by":"crossref","first-page":"88","DOI":"10.3109\/0284186X.2014.958528","article-title":"Dose intensified hypofractionated intensity-modulated radiotherapy with synchronous cetuximab for intermediate stage head and neck squamous cell carcinoma","volume":"54","author":"Thomson","year":"2015","journal-title":"Acta Oncol."},{"key":"10.1016\/j.critrevonc.2017.10.011_bib0545","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1111\/j.1468-3083.2009.03490.x","article-title":"Cetuximab-induced cutaneous toxicity","volume":"24","author":"Tomkov\u00e1","year":"2010","journal-title":"J Eur Acad Dermatology Venereol"},{"issue":"May (2)","key":"10.1016\/j.critrevonc.2017.10.011_bib0550","first-page":"1580","article-title":"Prognostic significance of p16 in locoregionally advanced head and neck cancer treated with concurrent 5-fluorouracil, hydroxyurea, cetuximab and intensity-modulated radiation therapy","volume":"27","author":"Tong","year":"2012","journal-title":"Oncol. Rep."},{"key":"10.1016\/j.critrevonc.2017.10.011_bib0555","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1007\/s11547-011-0716-3","article-title":"Acute toxicity in 14 patients with locally advanced head and neck squamous cell carcinoma treated with concurrent cetuximab and radiotherapy","volume":"117","author":"Valeriani","year":"2012","journal-title":"Radiol. Med."},{"issue":"August","key":"10.1016\/j.critrevonc.2017.10.011_bib0560","doi-asserted-by":"crossref","first-page":"214","DOI":"10.3389\/fonc.2014.00214","article-title":"Stereotactic body radiotherapy as primary treatment for elderly patients with medically inoperable head and neck cancer","volume":"4","author":"Vargo","year":"2014","journal-title":"Front. Oncol."},{"key":"10.1016\/j.critrevonc.2017.10.011_bib0565","doi-asserted-by":"crossref","first-page":"1695","DOI":"10.1056\/NEJMoa071028","article-title":"Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer","volume":"357","author":"Vermorken","year":"2007","journal-title":"N. Engl. J. Med."},{"issue":"May (5)","key":"10.1016\/j.critrevonc.2017.10.011_bib0570","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1093\/annonc\/mdw051","article-title":"Response-adapted volume de-escalation (RAVD) in locally advanced head and neck cancer","volume":"27","author":"Villaflor","year":"2016","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.critrevonc.2017.10.011_bib0575","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.radonc.2010.11.009","article-title":"Toxicity of cetuximab versus cisplatin concurrent with radiotherapy in locally advanced head and neck squamous cell cancer (LAHNSCC)","volume":"98","author":"Walsh","year":"2011","journal-title":"Radiother. Oncol."},{"issue":"October (10)","key":"10.1016\/j.critrevonc.2017.10.011_bib0580","doi-asserted-by":"crossref","first-page":"2036","DOI":"10.1093\/annonc\/mdu248","article-title":"Induction cetuximab, paclitaxel, and carboplatin followed by chemoradiation with cetuximab, paclitaxel, and carboplatin for stage III\/IV head and neck squamous cancer: a phase II ECOG-ACRIN trial (E2303)","volume":"25","author":"Wanebo","year":"2014","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.critrevonc.2017.10.011_bib0585","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1001\/jamaoncol.2016.5478","article-title":"Variant and cetuximab response in head and neck squamous cell cancer a secondary analysis of a randomized clinical trial","volume":"3","author":"Weidhaas","year":"2017","journal-title":"JAMA Oncol."},{"key":"10.1016\/j.critrevonc.2017.10.011_bib0590","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1016\/j.clon.2011.03.004","article-title":"Manageable early toxicity of cetuximab concurrent with radical radiotherapy for locally advanced head and neck cancer","volume":"23","author":"Wieczorek","year":"2011","journal-title":"Clin. Oncol. (R. Coll. Radiol.)"},{"key":"10.1016\/j.critrevonc.2017.10.011_bib0595","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1016\/j.oraloncology.2015.06.008","article-title":"Weekly cetuximab concurrent with IMRT aggravated radiation-induced oral mucositis in locally advanced nasopharyngeal carcinoma: results of a randomized phase II study","volume":"51","author":"Xu","year":"2015","journal-title":"Oral Oncol."},{"key":"10.1016\/j.critrevonc.2017.10.011_bib0600","doi-asserted-by":"crossref","first-page":"607","DOI":"10.4103\/0973-1482.126455","article-title":"Toxicity and outcomes in combined modality treatment of head and neck squamous cell carcinoma: cisplatin versus cetuximab","volume":"9","author":"Ye","year":"2013","journal-title":"J. Cancer Res. Ther."},{"key":"10.1016\/j.critrevonc.2017.10.011_bib0605","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.radonc.2016.05.028","article-title":"Optimal adaptive IMRT strategy to spare the parotid glands in oropharyngeal cancer","volume":"120","author":"Zhang","year":"2016","journal-title":"Radiother. Oncol."},{"issue":"January","key":"10.1016\/j.critrevonc.2017.10.011_bib0610","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1186\/s12885-016-2073-z","article-title":"Asian expert recommendation on management of skin and mucosal effects of radiation, with or without the addition of cetuximab or chemotherapy, in treatment of head and neck squamous cell carcinoma","volume":"16","author":"Zhu","year":"2016","journal-title":"BMC Cancer."},{"key":"10.1016\/j.critrevonc.2017.10.011_bib0615","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1007\/s00066-010-2149-7","article-title":"IMRT reirradiation with concurrent cetuximab immunotherapy in recurrent head and neck cancer","volume":"187","author":"Zwicker","year":"2011","journal-title":"Strahlentherapie Und Onkol"}],"container-title":["Critical Reviews in Oncology\/Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S104084281730149X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S104084281730149X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2022,8,6]],"date-time":"2022-08-06T00:17:58Z","timestamp":1659745078000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S104084281730149X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,12]]},"references-count":123,"alternative-id":["S104084281730149X"],"URL":"https:\/\/doi.org\/10.1016\/j.critrevonc.2017.10.011","relation":{},"ISSN":["1040-8428"],"issn-type":[{"value":"1040-8428","type":"print"}],"subject":[],"published":{"date-parts":[[2017,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Incidence of skin toxicity in squamous cell carcinoma of the head and neck treated with radiotherapy and cetuximab: A systematic review","name":"articletitle","label":"Article Title"},{"value":"Critical Reviews in Oncology\/Hematology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.critrevonc.2017.10.011","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}